DUBLIN, March 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that an abstract (Abstract #PB-48) reviewing interim clinical data from its ongoing Phase 1 study of NEOD001 in patients with immunoglobulin light chain (AL) amyloidosis and persistent organ dysfunction will be presented at the XIV International Symposium on Amyloidosis (ISA) in Indianapolis, Indiana. Data in the abstract was current as of January 7, 2014. The poster presentation will include data from the ongoing Phase 1 study as of late March. Prothena is developing NEOD001, a humanized novel monoclonal antibody designed to neutralize and clear soluble and insoluble amyloid aggregates in patients with AL. NEOD001 is being studied in an ongoing Phase 1 study. The abstract accepted for poster presentation is as follows: (Abstract #PB-48) Preliminary cardiac biomarker responses demonstrated in an ongoing phase 1 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction
- Presenter: Dr. Michaela Liedtke, Stanford Cancer Institute, Stanford, California
- Date: Tuesday, April 29
About ProthenaProthena Corporation plc is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. These potential therapies have a number of indications, including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in inflammatory diseases and metastatic cancers (PRX003). For more information, please visit www.prothena.com. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Section 27Aof the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to, among other things, our expectations regarding the nature and timing of our Phase 1 study of NEOD001, including disclosure of data from such study. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "plan," "predict," "project," "potential," "target," "will" and similar terms and phrases, including references to assumptions. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors including, but not limited to the risks and uncertainties described in Prothena's SEC filings, including the "Risk Factors" section of Prothena's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in Prothena's expectations.
CONTACT: Investors: Tran Nguyen, CFO 650-837-8535 IR@prothena.com Media: Anita Kawatra 646-256-5116 email@example.com